Compounded vs FDA-Approved Semaglutide

Q: Is compounded semaglutide FDA approved?

No. FDA says compounded drugs are not FDA approved.

	Compounded semaglutide	FDA-approved semaglutide
FDA status	Not FDA approved. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed ^[1].	FDA approved, with labels for Ozempic and Wegovy, among others ^{[5, 6]}.
Studied for	No FDA review of evidence before sale ^[1]. The data FDA cites are adverse event reports: 990 for compounded semaglutide as of May 31, 2026 ^[1].	Labeled uses include type 2 diabetes and its heart and kidney risks (Ozempic) and weight reduction (Wegovy) ^{[5, 6]}.
Route	May be dispensed in multi-dose vials for patients to self-administer. FDA has reports of dosing errors ^[1].	Under-the-skin injection once weekly (Ozempic, Wegovy) or a once-daily tablet (Wegovy tablets) ^{[5, 6]}.
Key trials	None reviewed by FDA. FDA says adverse events from compounded versions are underreported ^[1].	STEP 1, SELECT and SUSTAIN-6, among others ^{[7, 8, 9]}.
Salt forms	FDA says semaglutide sodium and semaglutide acetate are different active ingredients, with no known lawful basis for compounding ^[1].	Approved products contain semaglutide as reviewed in their labels ^{[5, 6]}.
Supply rules	Pharmacies may not regularly or in inordinate amounts make copies of a commercial drug ^[11]. FDA does not plan to act on four or fewer such prescriptions a month ^[2].	FDA declared the semaglutide injection shortage resolved on Feb 21, 2025 ^[2].

Compounded semaglutide is made by a pharmacy or outsourcing facility. It is not FDA approved, so FDA does not review it for safety, effectiveness or quality before it is sold ^[1]. FDA-approved semaglutide, sold as Ozempic and Wegovy among others, went through FDA review and has a label based on clinical trials ^{[5, 6]}.

What FDA review covers

Approved semaglutide has a label that sets its uses, doses and warnings. Ozempic is labeled for type 2 diabetes and to lower heart and kidney risks in some adults with diabetes ^[5]. Wegovy is labeled for use with a reduced calorie diet and more physical activity ^[6]. The labels list the routes: an under-the-skin shot, and for Wegovy also a daily tablet ^{[5, 6]}.

Compounded drugs skip this step. FDA says compounded drugs are not FDA approved ^[10]. Its GLP-1 page adds that FDA does not review them for safety, effectiveness or quality before they are marketed ^[1].

What evidence exists

The approved products rest on large trials. In STEP 1, 1,961 adults without diabetes took 2.4 mg weekly or placebo for 68 weeks. Body weight fell 14.9% vs 2.4% ^[7]. In SELECT, 17,604 adults with heart disease and overweight or obesity took part. Heart attack, stroke or heart death occurred in 6.5% on semaglutide vs 8.0% on placebo ^[8]. In SUSTAIN-6, 3,297 adults with type 2 diabetes were studied for heart outcomes ^[9].

Those results apply to the approved products. No FDA-reviewed trial covers a given compounded version ^[1]. What FDA does track for compounded versions is adverse event reports. As of May 31, 2026, FDA had received 990 reports tied to compounded semaglutide ^[1].

Safety issues FDA has flagged

FDA says compounded GLP-1 drugs may come in vials with many doses for a patient to self-administer. It has reports of dosing errors, some needing a hospital stay, when patients measured the wrong dose or clinicians miscalculated ^[1]. FDA also says these adverse events are underreported, because state-licensed pharmacies that are not outsourcing facilities do not have to report them to FDA ^[1].

Some products use salt forms. FDA says semaglutide sodium and semaglutide acetate are different active ingredients from those in approved drugs. FDA knows of no lawful basis for using them in compounding ^[1].

The rules since the shortage ended

Compounders had more room while the drug was in shortage. FDA declared the semaglutide injection shortage resolved on Feb 21, 2025 ^[2]. The 503B grace period ran until May 22, 2025. FDA said the 503A period had ended after a court denied an injunction on April 24, 2025 ^[2].

A 503A pharmacy may not regularly, or in inordinate amounts, make drugs that are essentially copies of a commercial product ^[11]. FDA says it does not plan to act on a compounder that fills four or fewer prescriptions of such a copy in a calendar month ^[2].

On Feb 6, 2026, FDA said it intends to act against compounded GLP-1 drugs mass-marketed as alternatives to approved ones. It also said ads may not call them generic versions of approved drugs ^[3]. On April 30, 2026, FDA proposed keeping semaglutide off the 503B bulks list. It said it would weigh public comments before a final decision ^[4].

For more, see the semaglutide page, 503A vs 503B pharmacies and the FDA Peptide Status Tracker ^[2].

Frequently asked questions

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness or quality before sale ^[1]. FDA says ads may not call them generic versions of approved drugs ^[3].

Is compounded semaglutide FDA approved?

No. FDA says compounded drugs are not FDA approved ^[10].

How many adverse events has FDA received for compounded semaglutide?

As of May 31, 2026, FDA had received 990 adverse event reports tied to compounded semaglutide ^[1].

Is semaglutide sodium the same as semaglutide?

No. FDA says semaglutide sodium and semaglutide acetate are different active ingredients from those in approved drugs ^[1].

Can pharmacies still compound semaglutide?

FDA ended the shortage on Feb 21, 2025. A 503A pharmacy may not regularly make copies of a commercial drug, but FDA does not plan to act on four or fewer such prescriptions a month ^{[2, 11]}.

What trials support FDA-approved semaglutide?

Trials include STEP 1 for weight, SELECT for heart risk in people without diabetes, and SUSTAIN-6 in type 2 diabetes ^{[7, 8, 9]}.

Why are dosing errors a concern with compounded semaglutide?

FDA says compounded GLP-1 drugs may come in multi-dose vials, and it has reports of patients and clinicians getting the dose wrong ^[1].